KRAS and cancer: Moreover, a substantial number of KRAS-mutant tumors have mutations in other cancer driver genes such as TP53, CDKN2A, and STK11. Studies in transgenic mice have found that activating mutations in KRAS predispose mice to early-onset lung adenocarcinoma [179, 180].